Mereo BioPharma Group (MREO) Projected to Post Quarterly Earnings on Tuesday

Mereo BioPharma Group (NASDAQ:MREO) is expected to be announcing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.0035) per share and revenue of $3.70 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 2:00 AM ET.

Mereo BioPharma Group (NASDAQ:MREO) last announced its earnings results on Tuesday, August 12th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $7.80 million. On average, analysts expect Mereo BioPharma Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mereo BioPharma Group Trading Down 2.4%

MREO traded down $0.05 during trading on Tuesday, reaching $1.82. The stock had a trading volume of 621,920 shares, compared to its average volume of 1,624,630. The stock’s 50 day moving average is $1.90 and its two-hundred day moving average is $2.12. The company has a market capitalization of $288.59 million, a price-to-earnings ratio of -25.96 and a beta of 0.41. Mereo BioPharma Group has a one year low of $1.47 and a one year high of $4.40.

Analyst Ratings Changes

Several research firms recently commented on MREO. JPMorgan Chase & Co. increased their price objective on Mereo BioPharma Group from $7.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. Zacks Research cut Mereo BioPharma Group from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mereo BioPharma Group in a research report on Wednesday, October 8th. Wall Street Zen raised Mereo BioPharma Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, Needham & Company LLC set a $5.00 target price on Mereo BioPharma Group and gave the stock a “buy” rating in a research report on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Institutional Trading of Mereo BioPharma Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in MREO. Marex Group plc bought a new stake in Mereo BioPharma Group in the 2nd quarter worth approximately $27,000. XTX Topco Ltd bought a new stake in Mereo BioPharma Group in the 2nd quarter worth approximately $188,000. Nomura Holdings Inc. bought a new stake in Mereo BioPharma Group in the 2nd quarter worth approximately $339,000. Paloma Partners Management Co purchased a new position in shares of Mereo BioPharma Group in the 2nd quarter worth approximately $804,000. Finally, Woodline Partners LP boosted its holdings in shares of Mereo BioPharma Group by 53.2% in the 1st quarter. Woodline Partners LP now owns 947,986 shares of the company’s stock worth $2,133,000 after purchasing an additional 329,202 shares during the period. Institutional investors own 62.83% of the company’s stock.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.